Answers are grounded in this paper and cite their sources.
Ocular bobbing is a rare eye movement disorder associated with destructive pontine lesions that can cause disabling oscillopsia and visual impairment, with no established treatment. We report a 76-year-old woman who developed ocular bobbing following a pontine infarction involving the left lateral pons with extension across the midline and into the left middle cerebellar peduncle, accompanied by bilateral horizontal gaze palsies, left sixth and seventh cranial nerve palsies, acquired pendular nystagmus, and strabismus. Because of persistent, functionally limiting oscillopsia, she underwent serial onabotulinumtoxinA injections into selected extraocular muscles, primarily targeting the bilateral vertical rectus muscles to reduce the vertical oscillatory component of ocular bobbing, with horizontal rectus injections adjusted as needed for sixth nerve palsy-related strabismus. Eleven injection sessions were performed between October 2022 and October 2025. Following treatment, the patient consistently reported improved visual stability and reduced oscillopsia, with benefit lasting approximately 6–8 weeks after each injection. Three-dimensional video-oculography demonstrated quantitatively smaller vertical oscillation amplitudes after treatment, with the greatest reduction observed 1.5 months after the second injection. Visual acuity remained relatively stable throughout treatment. Injections were performed without documented procedural complications; however, treatment-related changes in ocular alignment and motility occurred, including transient worsening of left hypotropia after the initial right inferior rectus injection. These effects underscore the need to distinguish procedural safety from the expected and potentially clinically significant ocular motor consequences of extraocular muscle chemodenervation. Serial extraocular muscle onabotulinumtoxinA injections were associated with reproducible subjective improvement in oscillopsia and objective reduction of ocular bobbing. This case suggests that extraocular muscle chemodenervation may represent a potential therapeutic approach for disabling ocular bobbing, although further study is needed to establish its efficacy, safety, and optimal treatment strategy.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: